Recent findings indicate that a certain drug did not successfully delay the progression of Alzheimer’s disease in trial participants. This outcome has been disappointing for the research community, as many had tempered expectations for a significant breakthrough. Alzheimer’s disease is known for its complexity and resistance to treatment, and often, substantial damage has occurred before individuals receive a diagnosis.
Despite this setback, some researchers maintain a degree of optimism. Studies suggest that GLP-1, a compound associated with certain drugs, may have beneficial effects on brain health, including reducing inflammation and enhancing communication between brain regions. There is still potential that GLP-1 medications could help prevent Alzheimer’s in individuals who are not yet showing cognitive decline.
In a separate line of inquiry, recent research has prompted questions regarding the safety of GLP-1 drugs around the time of pregnancy. Current guidance recommends discontinuing these medications two months before conception due, in part, to animal studies that indicate potential risks to fetal development. However, human impacts remain largely unstudied.
Among broader populations, there is evidence that individuals prescribed GLP-1s for weight loss often experience weight regain upon ceasing the medication. A recent study published in JAMA noted that pregnant individuals who had used GLP-1s during their weight loss efforts gained approximately 3.3 kg more than those who had not. Additionally, they appeared to face a heightened risk for several complications, including gestational diabetes, blood pressure disorders, and preterm birth. Further research is needed to understand the full implications of GLP-1s in various contexts, particularly concerning pregnancy.
Source: https://www.technologyreview.com/2025/11/28/1128511/what-we-still-dont-know-about-weight-loss-drugs/